EMA Review of Panobinostat (Farydak) for the Treatment of Adult Patients with Relapsed and/or Refractory Multiple Myeloma

On August 28, 2015, a marketing authorization valid through the European Union was issued for panobinostat, in combination with bortezomib and dexamethasone, for the treatment of adult patients with relapsed and/or refractory multiple myeloma who have received at least two prior regimens including b...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Oncologist
Päätekijät: Tzogani, Kyriaki, van Hennik, Paula, Walsh, Ita, De Graeff, Pieter, Folin, Annika, Sjöberg, Jan, Salmonson, Tomas, Bergh, Jonas, Laane, Edward, Ludwig, Heinz, Gisselbrecht, Christian, Pignatti, Francesco
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: AlphaMed Press 2017
Aiheet:
Regulatory Issues: EMA
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC5947444/
https://ncbi.nlm.nih.gov/pubmed/29192015
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2017-0301
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia